A drug called Nerlynx, which has been shown to reduce the risk of recurrence in HER2-positive early stage breast cancer patients, has recently been approved by the Therapeutic Goods Administration for sale in Australia.
This is another positive step forward in the fight against breast cancer.
Read Kate Harper’s story published on Perth Now, on 19 March 2019.
Kate is a 47 year old mother of young twin boys who was diagnosed with breast cancer in 2016. Under the care of Professor Arlene Chan, she has been part of a clinical trial for Nerlynx, which has shown a reduction in a woman’s five-year risk of the reoccurrence of HER2 positive breast cancer or death by 42 per cent.
“This is unique. This is the only drug, which has been shown when given after chemotherapy and trastuzumab, to reduce the risk of recurrence,” Prof Chan told AAP.
“That’s what every woman diagnosed with HER2 breast cancer would want to achieve,” she said.
***
